Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.09 EUR | -1.10% | -1.09% | -40.13% |
Business Summary
AsiDNA® is the first compound derived from platON®, a first-in-class inhibitor developed by the company. Based on a novel decoy and agonist mechanism acting upstream of multiple DDR pathways, it is highly differentiated from the tumor DNA damage response. Valerio Therapeutics is also developing OX425, a novel platON®-generated drug candidate optimized to be a next-generation PARP inhibitor, acting on both the DNA damage response and the activation of the immune response, without inducing resistance. OX425 is currently undergoing Investigational New Drug (IND)-enabling preclinical development.
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oncology Products
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +24.74% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Rest of the World
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +24.74% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shefali Agarwal
CEO | Chief Executive Officer | 50 | 01/21/01 |
Julien Miara
BRD | Director/Board Member | 41 | 17/20/17 |
Valérie Leroy
IRC | Investor Relations Contact | - | 01/16/01 |
Hui Ping Jiang
LAW | General Counsel | - | - |
Philippe Maitre
PRN | Corporate Officer/Principal | 68 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jacques Mallet
BRD | Director/Board Member | 64 | 14/21/14 |
Khalil Barrage
BRD | Director/Board Member | 59 | - |
Director/Board Member | 61 | 29/11/29 | |
Julien Miara
BRD | Director/Board Member | 41 | 17/20/17 |
Bryan Giraudo
BRD | Director/Board Member | 49 | 23/21/23 |
Shefali Agarwal
CEO | Chief Executive Officer | 50 | 01/21/01 |
Robert Coleman
BRD | Director/Board Member | 62 | 14/21/14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 154,364,273 | 106,900,017 ( 69.25 %) | 368,174 ( 0.2385 %) | 69.25 % |
Company contact information
Valerio Therapeutics SA
49, blvd. du Général Martial Valin
75015, Paris
+33 1 70 38 33 99
http://www.valeriotx.comSector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+54.07% | 809B | |
+38.95% | 621B | |
-7.05% | 351B | |
+15.44% | 319B | |
+5.72% | 289B | |
+14.21% | 238B | |
-0.45% | 221B | |
+14.58% | 218B | |
+7.42% | 166B |
- Stock Market
- Equities
- ALVIO Stock
- C4X Stock
- Company Valerio Therapeutics